光谱探测器CT碘密度阈值区分椎体骨转移瘤与健康表现的骨小梁的准确性
该回顾性单中心研究纳入43例伴骨转移的癌症患者和40例无骨转移患者,评估光谱探测器CT碘密度图区分椎体骨小梁转移瘤与健康表现骨小梁的效能。转移瘤碘密度均值5.5±0.9 mg/ml vs 健康骨小梁3.5±0.9 mg/ml,阈值4.5 mg/ml时敏感度90.7%、特异度77.5%、AUC 0.90;多因素模型纳入vBMD、碘密度噪声和椎静脉碘密度后AUC提升至0.98。
要点
- 骨转移瘤碘密度均值5.5±0.9 mg/ml高于健康骨小梁3.5±0.9 mg/ml,但两组重叠明显。
- 单因素阈值4.5 mg/ml区分转移瘤与健康骨小梁的AUC为0.90,敏感度90.7%、特异度77.5%。
- 年龄、腰椎体积骨密度、碘密度噪声和椎静脉碘密度影响碘密度测量,多因素模型AUC达0.98。
核心结论
- 光谱探测器CT碘密度图可对椎体骨小梁转移瘤与健康表现骨小梁实现统计学区分,校正年龄、腰椎vBMD、椎静脉碘密度和病灶异质性后判别效能提高。
研究设计与样本
- 回顾性单中心研究,纳入2016年6月至2017年3月门静脉期光谱探测器CT数据集,43例伴骨转移的连续癌症患者和40例无骨转移患者;以随访影像、MRI和/或骨闪烁显像定义目标病灶和未受累对照椎体。
关键影像表现/征象
- 骨转移瘤碘密度均值5.5±0.9 mg/ml,健康表现骨小梁碘密度均值3.5±0.9 mg/ml,两者差异有统计学意义(p < 0.0001),但重叠明显。
- 年龄(p < 0.0001)和腰椎体积骨密度(p < 0.05)在多因素模型中独立影响碘密度测量。
诊断标准与关键数值
- 单因素分析中,碘密度阈值4.5 mg/ml区分骨病灶的AUC为0.90,敏感度90.7%、特异度77.5%。
- 多因素回归模型纳入腰椎体积骨密度、碘密度噪声和椎静脉碘密度后,AUC为0.98。
- 原文提及碘密度阈值4.5 mg/ml(最具效能)至5.0 mg/ml(优化特异度)。
临床应用与阅片要点
- 测量椎体骨小梁碘密度时需关注年龄和腰椎体积骨密度对碘密度值的独立影响。
- 判读碘密度图时应考虑椎静脉碘密度和病灶异质性,多因素模型可提高判别效能。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To evaluate quantitative iodine density mapping (IDM) with spectral detector computed tomography (SDCT) as a quantitative biomarker for separation of vertebral trabecular bone metastases (BM) from healthy-appearing trabecular bone (HTB).
MATERIALS AND METHODS: IRB-approved retrospective single-center-study of portal venous SDCT datasets acquired between June 2016 and March 2017. Inclusion of 43 consecutive cancer patients with BM and 40 without. Target lesions and non-affected control vertebrae were defined using follow-up imaging, MRI, and/or bone scintigraphy. ID and standard deviation were determined with ROI measures by two readers in (a) bone metastases, (b) HTB of BM patients and controls, and (c) ID of various vessels. Volumetric bone mineral density (vBMD) of the lumbar spine and age were recorded. Multivariate ROC analyses und Wilcoxon test were used to determine thresholds for separation of BM and HTB. p < 0.05 was considered significant.
RESULTS: ID measurements of 40 target lesions and 83 reference measurements of HTB were acquired. Age (p < 0.0001) and vBMD (p < 0.05) affected ID measurements independently in multivariate models. There were significant differences of ID between metastases (n = 43) and HTB ID (n = 124; mean 5.5 ± 0.9 vs. 3.5 ± 0.9; p < 0.0001), however, with considerable overlap. In univariate analysis, increased ID discriminated bone lesions (AUC 0.90) with a maximum combined specificity/sensitivity of 77.5%/90.7% when applying a threshold of 4.5 mg/ml. Multivariate regression models improved significantly when considering vBMD, the noise of ID, and vertebral venous ID (AUC 0.98).
CONCLUSION: IDM of SDCT yielded a statistical separation of vertebral bone lesions and HTB. Adjustment for confounders such as age and lumbar vBMD as well as for vertebral venous ID and lesion heterogeneity improved discrimination of trabecular lesions.
KEY POINTS: • SDCT iodine density mapping provides the possibility for quantitative analysis of iodine uptake in tissue, which allows to differentiate bone lesions from healthy bone marrow. • Age and vBMD have a significant impact on iodine density measurements. • Iodine density measured in SDCT yielded highest sensitivity and specificity for the statistical differentiation of vertebral trabecular metastases and healthy trabecular bone using an iodine density threshold of 4.5 mg/ml (most performant)-5.0 mg/ml (optimized for specificity).
引用
- Borggrefe J, Neuhaus VF, Le Blanc M, et al. Accuracy of iodine density thresholds for the separation of vertebral bone metastases from healthy-appearing trabecular bone in spectral detector computed tomography. Eur Radiol. 2018. PMID: 30523450. doi:10.1007/s00330-018-5843-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。